Thrombin Inhibitor Market, By Type (Direct Thrombin Inhibitors, Indirect Thrombin Inhibitors), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation (AF), Others (stroke prevention, acute coronary syndrome, etc.)), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Thrombin inhibitors are anticoagulants (or are a class of medication that act as anticoagulants) that bind to and inhibit the activity of thrombin therefore prevent blood clot formation. They are used to prevent arterial and venous thrombosis, as well as to prevent and treat deep vein thrombosis and are used as prophylaxis in atrial fibrillation to avoid thromboembolism.
Market Dynamics:
Increasing prevalence/incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF), rise in demand for safe and effective treatment (due to increasing awareness among people worldwide), increase in research and development (R&D), and introduction of novel anticoagulants are major factors expected to propel growth of the global thrombin inhibitor market.
For instance, in June 2018, Mylan N.V. announced the U.S. launch of Bivalirudin for Injection, a generic version of Angiomax. The product, 250 mg single-dose vial, is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering Bivalirudin to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).
Key features of the study:
This report provides in-depth analysis of the global thrombin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global thrombin inhibitor market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, GlaxoSmithKline plc, AbbVie Inc., Portola Pharmaceuticals, Inc., CSL Behring, Johnson & Johnson, Sanofi S.A., Bayer AG, Pfizer Inc., Bristol Myers Squibb, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, and Aspen Pharmacare Holdings Limited, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global thrombin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thrombin inhibitor market.
Detailed Segmentation:
Global Thrombin Inhibitor Market, By Type:
Direct Thrombin Inhibitors
Indirect Thrombin Inhibitors
Global Thrombin Inhibitor Market, By Application:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Atrial Fibrillation (AF)
Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
Global Thrombin Inhibitor Market, By Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Company Profiles:
Eisai Co., Ltd.
Merck & Co., Inc.
Novartis International AG
GlaxoSmithKline plc
AbbVie Inc.
Portola Pharmaceuticals, Inc.
CSL Behring
Johnson & Johnson
Sanofi S.A.
Bayer AG
Pfizer Inc.
Bristol Myers Squibb
Boehringer Ingelheim GmbH
Daiichi Sankyo Company
Aspen Pharmacare Holdings Limited
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence or incidence of DVT, PE, and AF
- Lack of awareness among people about thrombin inhibitor
- Increasing demand for safe/effective thrombin inhibitors
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- 4. Global Thrombin Inhibitor Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
- 5. Global Thrombin Inhibitor Market, By Type, 2023-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- Direct Thrombin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
- Indirect Thrombin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
- 6. Global Thrombin Inhibitor Market, By Application, 2023-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
- Pulmonary Embolism (PE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
- Atrial Fibrillation (AF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
- Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
- 7. Global Thrombin Inhibitor Market, By Geography, 2023-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
- Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
- 8. Competitive Landscape
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Novartis International AG
- GlaxoSmithKline plc
- AbbVie Inc.
- Portola Pharmaceuticals, Inc.
- CSL Behring
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- Pfizer Inc.
- Bristol Myers Squibb
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company
- Aspen Pharmacare Holdings Limited
- Analyst Views
- 9. Section
- Research Methodology
- About us
- *Browse 24 market data tables and 28 figures on "Global Thrombin Inhibitor Market” - Europe forecast to 2030
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook